✦ LIBER ✦

Estimated medical cost reductions associated with apixaban in real-world patients with non-valvular atrial fibrillation

✍ Scribed by Amin, Alpesh; Stokes, Michael; Wu, Ning; Gatt, Elyse; Makenbaeva, Dinara; Wiederkehr, Daniel; Boulanger, Luke

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Estimated medical cost reductions associ

✍ Amin, Alpesh; Stokes, Michael; Makenbaeva, Dinara; Wiederkehr, Daniel; Wu, Ning; 📂 Article 📅 2014 🏛 Informa plc 🌐 English ⚖ 166 KB

PHS23 Direct Medical Costs Associated Wi

✍ Marfatia, S.; Sangole, N.; Munshi, S.; Tiwari, A.; Patel, M.; Suvarna, V.; Bhure 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 61 KB

Comparison of cost-effectiveness of anti

✍ Krejczy, Martin; Harenberg, Job; Marx, Svetlana; Obermann, Konrad; Frölich, Lutz 📂 Article 📅 2013 🏛 Springer US 🌐 English ⚖ 461 KB

PCV48 Clinical Outcomes and Costs Associ

✍ O. Baser; L. Wang 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 59 KB

Cost-Effectiveness Analysis of Apixaban

✍ Betegón Nicolás, L.; Escolar Albaladejo, G.; Canal Fontcuberta, C.; de Salas-Can 📂 Article 📅 2013 🏛 John Wiley and Sons 🌐 English ⚖ 61 KB

Cost-Effectiveness Analysis of Apixaban

✍ Canal Fontcuberta, C.; Escolar Albaladejo, G.; Betegón Nicolás, L.; de Salas-Can 📂 Article 📅 2013 🏛 John Wiley and Sons 🌐 English ⚖ 61 KB